Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally... Show more
Alvotech is a vertically integrated biotechnology company focused on developing and manufacturing biosimilars — lower-cost versions of complex biologic medicines. Headquartered in Reykjavik, Iceland, the company has transitioned from a pre-revenue developer into a global commercial player, with five products now generating revenue: biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab).
The company's core competitive advantage is breadth. Management describes a 32-asset pipeline, with several late-stage programs targeting limited-competition markets. In the biosimilar industry, first-to-market status often translates into higher market share and better pricing, which is why Alvotech's positioning on Simponi, Eylea high-dose, and Entyvio matters for its medium-term trajectory. A capital-light commercial model — partnering with companies such as Teva, Dr. Reddy's, and Fujifilm — lets Alvotech concentrate on research, development, and manufacturing while partners shoulder distribution costs. This structure supports margin expansion as launches scale, though it also means execution depends partly on partner performance.
The most consequential near-term events are regulatory. Alvotech resubmitted Biologics License Applications (BLAs) for AVT05 (a biosimilar to Simponi) and AVT06 (a biosimilar to Eylea), with FDA decisions anticipated in the fourth quarter of 2026. Its partner Dr. Reddy's has separately resubmitted the BLA for AVT03 (Prolia/Xgeva). These filings follow Complete Response Letters (CRLs) — formal FDA notices that an application cannot be approved — tied to manufacturing observations at the Reykjavik facility rather than product safety or efficacy. Management has guided to resubmission-triggered six-month approval clocks, positioning year-end as a critical catalyst window.
Beyond 2026, Alvotech expects to file a U.S. BLA for its Entyvio biosimilar, a roughly $7 billion global market where it anticipates a first-mover advantage, with launches possible in 2027. The Eylea high-dose program and additional undisclosed assets could sustain a multi-year launch cadence.
Analyst sentiment has been broadly constructive but not uniform. Jefferies initiated coverage with a Buy rating and a $9 price target in November 2026, while Barclays maintained a Buy with an $8 target and UBS raised its target from $6 to $8. Earlier in 2026, several firms trimmed targets after the CRLs, reflecting both optimism about the pipeline and caution over execution risk. This mix suggests analyst expectations have firmed as regulatory visibility improves, even as price targets remain below pre-setback levels.
Alvotech's outlook is closely tied to healthcare policy and drug-pricing dynamics. Governments and insurers in the U.S. and Europe continue to promote biosimilar adoption to contain spending on blockbuster biologics, a structural tailwind for the industry. Inflation-reduction efforts and pricing reforms in the U.S. may accelerate substitution toward lower-cost biosimilars, supporting volume growth even if net pricing compresses over time.
Interest rates matter primarily through their effect on valuation and financing. As a capital-intensive biotech with a heavy research-and-development (R&D) burden, Alvotech's long-duration cash flows make its shares sensitive to rate expectations. However, its improving EBITDA (earnings before interest, taxes, depreciation, and amortization) profile and reaffirmed 2026 guidance of $650 million to $700 million in revenue reduce near-term funding risk. Patent litigation — particularly 14 patents in dispute with Johnson & Johnson over Simponi — represents a key legal uncertainty that could influence launch timing.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking Alvotech and other names, the Trend Prediction Engine offers a data-driven complement to fundamental analysis.
Looking toward 2026 and beyond, Alvotech's trajectory hinges on converting its pipeline breadth into commercial launches. Management reaffirmed full-year 2026 guidance of $650 million to $700 million in revenue and $180 million to $200 million in adjusted EBITDA, implying a sharp revenue ramp in the second half as manufacturing normalizes and milestone payments are recognized. Execution against this guidance will be a key test of whether first-half production slowdowns were temporary rather than structural.
Longer term, several themes warrant attention. Market expansion opportunities include direct U.S. commercialization of select assets, such as HEMLIBRA and IMFINZI through a licensing agreement with Lotus, marking a shift from a purely business-to-business model. Cost structure and margin sustainability will depend on manufacturing capacity utilization and the economics of the Fujifilm second source, expected to be operational in the second half of 2027. Competitive threats include rivals with similarly large pipelines, though industry consolidation and exits have thinned the field. Finally, capital allocation priorities and continued patent litigation will shape how quickly Alvotech can translate its development advantages into sustained free cash flow.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.
| Ticker / NAME | Correlation To ALVO | 1D Price Change % | ||
|---|---|---|---|---|
| ALVO | 100% | +5.13% | ||
| EBS - ALVO | 30% Poorly correlated | +0.35% | ||
| CRON - ALVO | 24% Poorly correlated | -3.25% | ||
| XERS - ALVO | 23% Poorly correlated | +0.24% | ||
| PAHC - ALVO | 22% Poorly correlated | -2.64% | ||
| SIGA - ALVO | 22% Poorly correlated | +4.01% | ||
More | ||||
| Ticker / NAME | Correlation To ALVO | 1D Price Change % |
|---|---|---|
| ALVO | 100% | +5.13% |
| Pharmaceuticals: Generic industry (81 stocks) | 5% Poorly correlated | -2.67% |
Industry PharmaceuticalsGeneric
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALVO declined for three days, in 233 of 294 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 71 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for ALVO entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALVO's RSI Indicator exited the oversold zone, 25 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ALVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.